Luteinizing hormone releasing hormone human acetate salt (LHRH)
(Synonyms: 醋酸戈那瑞林) 目录号 : GP10088MMP-2 和 MMP-9 的激活剂,选择性
Cas No.:71447-49-9
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Luteinizing hormone releasing hormone human acetate salt (LHRH) is a selective acitivator of MMP-2 and MMP-9 [1, 2].
Luteinizing hormone-releasing hormone (LHRH), also known as Gonadotropin-releasing hormone (GnRH) is a trophic peptide hormone which secreted by GnRH neurons and plays an important role in the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary [3].
MMP-2 (matrix metalloproteinase-2) and MMP-9 (matrix metalloproteinase-9) belong to the MMP family that play an important role in the breakdown of extracellular matrix (ECM) in normal physiological processes, for example, embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis [2].
When tested with Ishikawa and ECC-1 cell lines, LHRH resulted in the increase of MMP-9 expression which induced cell invasion and it was also showed that GPR101 mediated the LHRH activity and cooperated to function in the metastatic potential of endometrial cancer cells [1]. In human decidual endometrial stromal cells, LHRH with its receptor induced the activation of MMP-2 and MMP-9 [2].
References:
[1]. Cho-Clark, M., et al., GnRH-(1-5) Activates Matrix Metallopeptidase-9 to release Epidermal Growth Factor and Promote Cellular Invasion. Mol Cell Endocrinol, 2015.
[2]. Wu, H.M., et al., Gonadotropin-releasing hormone type II (GnRH-II) agonist regulates the motility of human decidual endometrial stromal cells: possible effect on embryo implantation and pregnancy. Biol Reprod, 2015. 92(4): p. 98.
[3]. Garnick, M.B. and M. Campion, Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group. Mol Urol, 2000. 4(3): p. 275-7.
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.8458 mL | 4.2291 mL | 8.4582 mL |
5 mM | 0.1692 mL | 0.8458 mL | 1.6916 mL |
10 mM | 0.0846 mL | 0.4229 mL | 0.8458 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。